| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 18.08. | Biodexa Pharmaceuticals PLC: Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) | August 18, 2025 Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) Opportunity to be First Mover in $7.3Bn Addressable Market... ► Artikel lesen | |
| 18.08. | Biodexa Pharmaceuticals Plc - 6-K, Report of foreign issuer | ||
| 31.07. | Biodexa vollzieht Anpassung des ADR-Verhältnisses auf 1:100.000 Stammaktien | ||
| 31.07. | Biodexa completes ADR ratio change to 1:100,000 ordinary shares | ||
| 31.07. | Biodexa Pharmaceuticals PLC: ADR Ratio Change Effective | July 31, 2025 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") ADR Ratio Change Effective ADSs Outstanding Post Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical... ► Artikel lesen |
| Unternehmen / Aktien | Kurs | % |
|---|---|---|
| BIODEXA PHARMACEUTICALS PLC ADR | 5,540 | +0,54 % |
